RxDoctor Payments Data

Bryan Harris, MD

Dermatology · Lubbock, TXNPI 1174553556

Payments from drug & device makers

$130,824in general payments, 2019–2025

Across 790 payments — averaging $165.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$115K
  • AbbVie$3K
  • Regeneron Healthcare Solutions, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Johnson & Johnson$1K
  • plus $6K from 27 others
$930in research payments, 2019–2025

Across 2 payments — averaging $465.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$930

What the payments were for

  • Food & beverage$16,77197%
  • Education$5153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,824 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$304,783
Medicare patients
951
Services billed
7,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$238,383
Humira(Cf) PenAdalimumab11$115,172
Dupixent PenDupilumab27$100,746
Dupixent SyringeDupilumab17$98,356
Cosentyx Unoready PenSecukinumab11$80,461
Fluocinonide210$7,864
Clobetasol Propionate105$4,146
Triamcinolone Acetonide205$3,394
Fluticasone Propionate112$2,283
Clindamycin Phosphate47$2,135
Cephalexin233$1,249
Doxycycline Hyclate82$1,164
ValacyclovirValacyclovir Hcl61$955
Metronidazole19$905
Tretinoin13$796

Paid to pharmacies, not to this prescriber.

Other dermatology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →